The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-28 and is reviewed periodically as new material appears.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
== History == Dalbavancin has undergone a phase-III clinical trial for adults with complicated skin infections, but in December 2007, the US Food and Drug Administration (FDA) said more data were needed before approval. Pfizer withdrew its marketing applications to conduct another phase-III clinical trial in September 2008. Durata Therapeutics acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ABSSSIs. Preliminary results in 2012 were promising. About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to vancomycin. In May 2014, dalbavancin was approved for medical use in the United States for ABSSSIs, including MRSA and Streptococcus pyogenes infections.
The negotiations ended in deadlock, and Leibold suggests that Chiang deliberately sided with Liu over the Tibetans in order to gain his support against Communist forces during the Long March—who had managed to slip through Xikang anyway. Liu's later stance on Tibet was more pragmatic, arguing that development of Xikang was a prerequisite for dealing with Tibet. Here, he attempted to build connections with Tibetan elites through shared Buddhist ties and leverage the tea trade to strengthen economic relations. Every year or so after 1940, Liu would send around 30-40,000 yuan worth of tea to the three great monasteries of Tibet as offerings to the 14th Dalai Lama. Liu maintained a military presence on the border with Tibet, which he would later use to justify his non-participation in the Second Sino-Japanese War. In late 1942, Chiang Kai-shek ordered Liu, as well as Ma Bufang in Qinghai, to deploy more troops on the border for the purposes of launching a military campaign against Tibet, which Liu accepted on the condition that he be granted extra military provisions and to personally take command of any reinforcements the central government would send. Plans for the campaign were eventually abandoned. Much later, it would be revealed through released materials from the Academica Historica that the Tibetan campaign was actually a pretext for the Chongqing government to assert direct control over Xikang.
=== Marketing === An Interactional Justice Model may be used to test the effects of willingness to talk with a doctor about clinical trial enrollment. Results found that potential clinical trial candidates were less likely to enroll in clinical trials if the patient is more willing to talk with their doctor. The reasoning behind this discovery may be patients are happy with their current care. Another reason for the negative relationship between perceived fairness and clinical trial enrollment is the lack of independence from the care provider. Results found that there is a positive relationship between a lack of willingness to talk with their doctor and clinical trial enrollment. Lack of willingness to talk about clinical trials with current care providers may be due to patients' independence from the doctor. Patients who are less likely to talk about clinical trials are more willing to use other sources of information to gain a better insight of alternative treatments. Clinical trial enrollment should be motivated to utilize websites and television advertising to inform the public about clinical trial enrollment.
EC 1, Oxidoreductases: catalyze oxidation/reduction reactions EC 2, Transferases: transfer a functional group (e.g. a methyl or phosphate group) EC 3, Hydrolases: catalyze the hydrolysis of various bonds EC 4, Lyases: cleave various bonds by means other than hydrolysis and oxidation EC 5, Isomerases: catalyze isomerization changes within a single molecule EC 6, Ligases: join two molecules with covalent bonds. EC 7, Translocases: catalyze the movement of ions or molecules across membranes, or their separation within membranes. These sections are subdivided by other features such as the substrate, products, and chemical mechanism. An enzyme is fully specified by four numerical designations. For example, hexokinase (EC 2.7.1.1) is a transferase (EC 2) that adds a phosphate group (EC 2.7) to a hexose sugar, a molecule containing an alcohol group (EC 2.7.1).
==== United States ==== Under the Controlled Substances Act, oxycodone is a Schedule II controlled substance whether by itself or part of a multi-ingredient medication. The Drug Enforcement Administration (DEA) lists oxycodone both for sale and for use in manufacturing other opioids as ACSCN 9143 and in 2013 approved the following annual aggregate manufacturing quotas: 131.5 metric tons for sale, down from 153.75 in 2012, and 10.25 metric tons for conversion, unchanged from the previous year. In 2020, oxycodone possession was decriminalized in the U.S. state of Oregon.
Sources: en.wikipedia.org
== Mechanism of action == Omacetaxine mepesuccinate is a protein translation inhibitor. It inhibits protein translation by preventing the initial elongation step of protein synthesis. It interacts with the ribosomal A-site and prevents the correct positioning of amino acid side chains of incoming aminoacyl-tRNAs. Omacetaxine mepesuccinate acts only on the initial step of protein translation and does not inhibit protein synthesis from mRNAs that have already commenced translation.
Kato K, Kawahara K, Takahashi T, Kakinuma A (1980). "Purification of an α-amino acid ester hydrolase from Xanthomonas citri". Agric. Biol. Chem. 44: 1069–1074. doi:10.1271/bbb1961.44.1069. Kato K, Kawahara K, Takahashi T, Kakinuma A (1980). "Substrate specificity of an α-amino acid ester hydrolase from Xanthomonas citri". Agric. Biol. Chem. 44: 1075–1081. doi:10.1271/bbb1961.44.1075. Takahashi T, Yamazaki Y, Kato K (1974). "Substrate specificity of an α-amino acid ester hydrolase produced by Acetobacter turbidans A.T.C.C. 9325". Biochem. J. 137 (3): 497–503. doi:10.1042/bj1370497. PMC 1166149. PMID 4424889.
The origin and usage of the term metalloid is convoluted. The name was popularized by Jöns Berzelius in the early 19th century, but he did not use it in the current meaning, but rather for a diverse group of nonmetal elements. James Apjohn's "Manual of Metalloids" published in 1864 divided all elements into either metals or metalloids. Since the mid-20th century it has been used to refer to intermediate or borderline chemical elements. The International Union of Pure and Applied Chemistry (IUPAC) previously recommended abandoning the term metalloid, and suggested using the term semimetal instead. Despite the recommendation, the term metalloid was increasingly used in the literature in 1970–2010, while semimetal remained less popular. Use of the term semimetal has more recently been discouraged by Atkins et al. as it has a more common meaning that refers to the electronic band structure of a substance rather than the overall classification of an element. The most recent IUPAC publications on nomenclature and terminology do not include any recommendations on the usage of the terms metalloid or semimetal.
=== Cookbooks === American Gastronomy: An Illustrated Portfolio of Recipes and Culinary history (1974), ISBN 978-0809283415 The Bakery Restaurant Cookbook (1980), ISBN 978-0843621952 The Chef's New Secret Cookbook (1975), ISBN 978-0809283545 The Chef's Secret Cook Book: A Practical, Personal Invitation to Classic Cookery (1971), ISBN 978-0812902136 Sears Gourmet Cooking Forum (1969)
Large very-low-density lipoprotein particles (VLDL-P) Small low-density lipoprotein particles (LDL-P) Large high-density lipoprotein particles (HDL-P) VLDL size LDL size HDL size These markers assess lipid metabolism linked to insulin resistance, in which cells respond poorly to insulin, often preceding type 2 diabetes and cardiovascular disease. Multiple studies, reported that it predicts future type 2 diabetes risk effectively, even outperforming traditional markers like fasting glucose in some cases. The LP-IR score offers early detection of insulin resistance, even in people with normal blood glucose, making it useful for preventive health strategies. It is simple, affordable, and doesn't require insulin or glucose measurements, avoiding issues with insulin assay variability.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.